SCHEMBL2122995

SCHEMBL2122995

CCNc1ccncc1C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.57
MKNK2 Q9HBH9 1/20 0.57
SIRT3 Q9NTG7 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
AOC1 P19801 1/20 0.49
AOC3 Q16853 1/20 0.49
KDM4C Q9H3R0 8/20 0.45
KDM6B O15054 4/20 0.45
IRAK4 Q9NWZ3 1/20 0.43
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4A O75164 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TGFBR1 P36897 1/20 0.40
CDC7 O00311 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22732130 0.84 SIRT3 (0.51) MKNK1MKNK2SIRT3TDP1KDM4C
SCHEMBL3712114 0.83 KDM4C (0.62) MKNK1MKNK2SIRT3TDP1KDM4C
SCHEMBL1585529 0.83 SIRT3 (0.50) MKNK1MKNK2SIRT3TDP1KDM4C
SCHEMBL3569822 0.82 SIRT3 (0.61) MKNK1MKNK2SIRT3TDP1AOC1
SCHEMBL31678615 0.82 NUDT1 (0.51) MKNK1MKNK2SIRT3TDP1AOC1
SCHEMBL21767777 0.82 KDM4E (0.53) MKNK1MKNK2AOC1AOC3KDM4C
SCHEMBL28284470 0.81 SIRT3 (0.49) MKNK1MKNK2SIRT3TDP1KDM4C
SCHEMBL662028 0.80 SIRT3 (0.58) MKNK1MKNK2SIRT3TDP1KDM4C
SCHEMBL6757557 0.80 SIRT3 (0.58) MKNK1MKNK2SIRT3TDP1KDM4C
SCHEMBL3723389 0.80 SIRT3 (0.47) MKNK1MKNK2SIRT3TDP1KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270190-A1 KIT INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-08-28 US disclosed
US-20120094986-A1 ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-04-19 US disclosed
EP-1525201-A1 BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR Pfizer Products Inc. (US) 2005-04-27 EP disclosed
WO-2004009588-A1 BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR PFIZER PRODUCTS INC. (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270190-A1 KIT INHIBITORS KIT, ABL1, APC MKNK1 568/4885MKNK2 743/4885SIRT3 4686/4885
US-20120094986-A1 ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF NAMPT, NQO1, NNT MKNK1 1381/4885MKNK2 1315/4885SIRT3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.